Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Pharmaceuticals SPDR (NY: XPH )

46.57 +0.23 (+0.50%)
Official Closing Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Pharmaceuticals SPDR

AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu. 
Via MarketBeat
Topics ETFs
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local governments,... 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
Organon Beats On Q1, Women's Health Leads the Charge
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared. 
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
3 Pharmaceutical ETFs That Could Be Due For A Rebound
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of bu... 
Via Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
Pharma ETFs Gain Post Q1 Earnings
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
3 Pharma Stocks Yielding Over 3%
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries. 
Via Talk Markets
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
The Bear Market Is Already Here – But Not For Dividend Investors
While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months. 
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
Via Talk Markets
The Cost Of Saving The Economy: $1.7 Billion Per Hour Every Hour
the Fed has bought $4 trillion bonds in the past 18 months, twice the amount the US spent on War in Afghanistan past 20 years as it, and other global central banks, have spent $834 million every hour... 
Via Talk Markets
Topics Bonds Economy
Exposures Debt Markets Interest Rates
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Via Talk Markets
Exposures COVID-19
3 Top Pharma Stocks to Buy This Month
In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19. 
Via Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Via Talk Markets
3 Pharmaceutical ETFs That Could Be Due For A Rebound
Here are three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. 
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.